Biosynthetic platform for cardioprotective gene expression using immature heart tissue

• US 20040220125A1
• Filed: 05/02/2003
• Published: 11/04/2004
• Est. Priority Date: 05/02/2003
• Status: Abandoned Application

• Current Assignee: Hospital For SICK Children
• Original Assignee: Hospital For SICK Children
• Inventors: Takahashi, Mark, Van Arsdell, Glen, Coles, John G.
• Application Number:
  US10/429,656
• Publication Number:
  US 20040220125A1
• Time in Patent Office: Days
• US Class Current: 514/44
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The present invention is directed toward identification of cardioprotective gene programs in the neonatal heart. Specifically, the newborn (immature) heart or alternatively fetal heart has been recognized as having an increased resistance to pathophysiological forms of stress, e.g. hypoxic stress. The pattern of gene expression in immature heart subject to naturally occurring hemodynamic and hypoxic stress, e.g. that associated with obstructive congenital heart disease, is herein revealed by differential gene profiling; and the induction of a cardioprotective gene pattern, and particularly useful subsets thereof, in the heart chronically adapted to stress is confirmed. Thus, the chronically stressed immature heart provides a novel biosynthetic platform for cardioprotective gene expression, useful as a basis for the development of diagnostic and therapeutic modalities.

Claims

1. A cardioprotective gene network which consists essentially of a combination of nucleic acid sequences which are up-regulated and down-regulated in immature heart tissue as a result of naturally occurring disease states:

wherein said up-regulated nucleic acid sequences consist of Hs.75640, Hs.356717, Hs.356717, Hs.111779, Hs.119571, Hs.111779, Hs.226103, Hs.75617, Hs.75636, Hs.152931, Hs.89525,Hs.334842,Hs.7940,Hs.433622, Hs.182507, Hs.119571, Hs.2076, Hs.74405, Hs.17681, Hs.108885, Hs.23168, Hs.75248, Hs.326035, Hs.10739, Hs.356350, Hs.15725, Hs.142442, Hs.159154, Hs.105779, Hs.349109, Hs.300711, Hs.107125, Hs.116992, Hs.2053, Hs.80350, Hs.75975; and

wherein said down-regulated nucleic acid sequences consist of Hs.177776, Hs.270956, Hs.75297, and Hs.28427.

6. A process for diagnosing hypertrophic heart disease in a patient comprising:

obtaining a characteristic differentially expressed cardiac nucleic acid sequence profile from said patient; and

comparing said profile to said cardioprotective gene network defined in claim 1;

whereby hypertrophic heart disease is diagnosed.

2. The cardioprotective gene network of claim 2, wherein said naturally occurring disease state is obstructive congenital heart disease.

3. A process for identification of a cardioprotective gene program in the immature heart comprising:

providing a sample of immature heart tissue which has been subjected to naturally occurring, chronic hemodynamic and/or hypoxic stress;

carrying out differential gene expression profiling on said sample; and

determining a pattern of up-regulated and down-regulated nucleic acid sequences therein;

whereby a differentially expressed profile of nucleic acid sequences constituting a cardioprotective gene program is identified.

4. The process of claim 3, wherein said naturally occurring, chronic hemodynamic and/or hypoxic stress is associated with obstructive congenital heart disease.

5. The process of claim 3, wherein said cardioprotective gene program simultaneously exhibits a combination of evident functional clusters including both up-regulated and down-regulated nucleic acid sequences evidencing anti-hypertrophic, anti-fibrotic and pro-vasodilatory programs.